Antwerp University Hospital
The incidence of cardiovascular events and revascularizations in patients treated with Immune Checkpoint Inhibitors in Belgium.
2023
Edegem
Study by C. Franssen: Immune Checkpoint Inhibitors (ICI) have revolutionized cancer treatment. Recent reports suggest a threefold increased risk in acute coronary syndromes upon ICI treatment, which is relevant since indications increase. This project studies the Belgian situation, where 30000 patients received ICI treatment. Data will be provided by the Intermutualistisch Agentschap – Agence Intermutualiste (IMA-AIM), Statbel and the Belgian Cancer Registry and focus on revascularizations, and cardiovascular death.